Enlivex Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -85 | -90 | -161 | |
EBITDA | -2,993 | -3,414 | -2,958 | |
EBIT | -3,078 | -3,504 | -3,119 | |
Net Income | -1,868 | -3,452 | -5,176 | -2,602 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -1,205 | -4,656 | -4,119 | -2,626 |
Cash | 1,892 | 2,053 | 3,301 | 2,772 |
Basic Shares | 23,855 | 21,895 | 23,650 | 21,278 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -545 | -835 | -777 | -546 |
EBITDA | -14,469 | -28,219 | -25,020 | -18,742 |
EBIT | -15,014 | -29,054 | -25,797 | -19,288 |
Net Income | -15,014 | -29,068 | -31,060 | -14,468 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -13,111 | -23,759 | -32,075 | -19,167 |
Cash | 3,301 | 813 | 47,822 | 11,202 |
Basic Shares | 20,513 | 18,574 | 18,394 | 17,859 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.11 |
2025-03-31 | -$0.15 |
2024-12-31 | -$0.23 |
